- Home
- LAC vs TRML Comparison
LAC vs TRML Comparison
Compare LAC & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- TRML
- Stock Information
- Founded
- LAC 2023
- TRML 2021
- Country
- LAC Canada
- TRML United States
- Employees
- LAC N/A
- TRML N/A
- Industry
- LAC Metal Mining
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- LAC Basic Materials
- TRML Health Care
- Exchange
- LAC Nasdaq
- TRML Nasdaq
- Market Cap
- LAC 722.6M
- TRML 598.9M
- IPO Year
- LAC N/A
- TRML N/A
- Fundamental
- Price
- LAC $2.85
- TRML $47.60
- Analyst Decision
- LAC Buy
- TRML Hold
- Analyst Count
- LAC 4
- TRML 11
- Target Price
- LAC $4.06
- TRML $46.95
- AVG Volume (30 Days)
- LAC 6.0M
- TRML 1.6M
- Earning Date
- LAC 11-06-2025
- TRML 11-06-2025
- Dividend Yield
- LAC N/A
- TRML N/A
- EPS Growth
- LAC N/A
- TRML N/A
- EPS
- LAC N/A
- TRML N/A
- Revenue
- LAC N/A
- TRML N/A
- Revenue This Year
- LAC N/A
- TRML N/A
- Revenue Next Year
- LAC N/A
- TRML N/A
- P/E Ratio
- LAC N/A
- TRML N/A
- Revenue Growth
- LAC N/A
- TRML N/A
- 52 Week Low
- LAC $2.28
- TRML $11.56
- 52 Week High
- LAC $5.20
- TRML $47.69
- Technical
- Relative Strength Index (RSI)
- LAC 49.50
- TRML 94.39
- Support Level
- LAC $2.74
- TRML $22.31
- Resistance Level
- LAC $3.02
- TRML $47.69
- Average True Range (ATR)
- LAC 0.13
- TRML 1.28
- MACD
- LAC -0.01
- TRML 2.70
- Stochastic Oscillator
- LAC 37.10
- TRML 99.65
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, which is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass is under construction and expected to begin production in 2028. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.